Do We Need to Hold Aspirin Before Cataract Surgery? A Systematic Review and Meta-Analysis of 65,196 Subjects.

IF 16.4 1区 化学 Q1 CHEMISTRY, MULTIDISCIPLINARY Accounts of Chemical Research Pub Date : 2024-11-01 DOI:10.1080/08820538.2024.2420969
Mohamed Abo Zeid, Amr Elrosasy, Ahmad Alkheder, Hazim Alkousheh, Mohammad Al Diab Al Azzawi, Shrouk F Mohamed, Ameen Alkhateeb, Hashem Abu Serhan
{"title":"Do We Need to Hold Aspirin Before Cataract Surgery? A Systematic Review and Meta-Analysis of 65,196 Subjects.","authors":"Mohamed Abo Zeid, Amr Elrosasy, Ahmad Alkheder, Hazim Alkousheh, Mohammad Al Diab Al Azzawi, Shrouk F Mohamed, Ameen Alkhateeb, Hashem Abu Serhan","doi":"10.1080/08820538.2024.2420969","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Cataract surgery is a common operation, typically carried out on older adults who have many comorbid medical conditions. Many of these patients may be undergoing aspirin therapy for diverse cardiovascular causes. Nevertheless, there is ongoing controversy regarding the administration of aspirin therapy during the perioperative period, as there are concerns regarding the risk of bleeding problems compared to thromboembolic events. Although aspirin is commonly used, there is no agreement on whether to continue or stop taking it before cataract surgery. This systematic review and meta-analysis attempt to assess the safety of continuing or discontinuing aspirin in the setting of cataract surgery.</p><p><strong>Methods: </strong>We conducted a systematic review and meta-analysis following PRISMA guidelines. Four databases were searched until January 25, 2024, for studies assessing the safety and efficacy of aspirin continuation or discontinuation before cataract surgery. The risk ratios (RR) of the extracted data and their 95% confidence interval (95% CI) were pooled using RevMan 5.4 software. We registered our protocol in the International Prospective Register of Systematic Reviews (PROSPERO) (registration number: CRD42024529986).</p><p><strong>Results: </strong>We included nine studies with a total of 65,196 patients comprising various study designs and global populations. The analysis revealed a significant increase in subconjunctival hemorrhage risk with aspirin continuation (RR: 1.74, 95% CI: 1.22, 2.50, <i>p</i> = .002). However, the risk of hyphema, retrobulbar hemorrhage, vitreous hemorrhage, intraocular pressure spike, corneal edema, posterior capsule rupture, and visual acuity changes did not significantly differ between aspirin continuation and discontinuation or aspirin and placebo groups.</p><p><strong>Conclusion: </strong>Although the use of aspirin before cataract surgery raises the likelihood of subconjunctival bleeding, it does not increase the risk of potentially sight-threatening bleeding events. We recommend continuation of aspirin in patients undergoing cataract surgery.</p>","PeriodicalId":1,"journal":{"name":"Accounts of Chemical Research","volume":null,"pages":null},"PeriodicalIF":16.4000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Accounts of Chemical Research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/08820538.2024.2420969","RegionNum":1,"RegionCategory":"化学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CHEMISTRY, MULTIDISCIPLINARY","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: Cataract surgery is a common operation, typically carried out on older adults who have many comorbid medical conditions. Many of these patients may be undergoing aspirin therapy for diverse cardiovascular causes. Nevertheless, there is ongoing controversy regarding the administration of aspirin therapy during the perioperative period, as there are concerns regarding the risk of bleeding problems compared to thromboembolic events. Although aspirin is commonly used, there is no agreement on whether to continue or stop taking it before cataract surgery. This systematic review and meta-analysis attempt to assess the safety of continuing or discontinuing aspirin in the setting of cataract surgery.

Methods: We conducted a systematic review and meta-analysis following PRISMA guidelines. Four databases were searched until January 25, 2024, for studies assessing the safety and efficacy of aspirin continuation or discontinuation before cataract surgery. The risk ratios (RR) of the extracted data and their 95% confidence interval (95% CI) were pooled using RevMan 5.4 software. We registered our protocol in the International Prospective Register of Systematic Reviews (PROSPERO) (registration number: CRD42024529986).

Results: We included nine studies with a total of 65,196 patients comprising various study designs and global populations. The analysis revealed a significant increase in subconjunctival hemorrhage risk with aspirin continuation (RR: 1.74, 95% CI: 1.22, 2.50, p = .002). However, the risk of hyphema, retrobulbar hemorrhage, vitreous hemorrhage, intraocular pressure spike, corneal edema, posterior capsule rupture, and visual acuity changes did not significantly differ between aspirin continuation and discontinuation or aspirin and placebo groups.

Conclusion: Although the use of aspirin before cataract surgery raises the likelihood of subconjunctival bleeding, it does not increase the risk of potentially sight-threatening bleeding events. We recommend continuation of aspirin in patients undergoing cataract surgery.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
白内障手术前需要服用阿司匹林吗?对 65,196 例受试者的系统回顾和 Meta 分析。
目的:白内障手术是一种常见的手术,通常是为患有多种并发症的老年人实施。其中许多患者可能因各种心血管疾病正在接受阿司匹林治疗。然而,围手术期使用阿司匹林治疗一直存在争议,因为人们担心出血问题的风险高于血栓栓塞事件。虽然阿司匹林是常用药物,但对于在白内障手术前是继续服用还是停止服用阿司匹林还没有达成一致意见。本系统综述和荟萃分析试图评估在白内障手术中继续或停止服用阿司匹林的安全性:我们按照 PRISMA 指南进行了系统回顾和荟萃分析。截至 2024 年 1 月 25 日,我们在四个数据库中检索了评估白内障手术前继续服用或停用阿司匹林的安全性和有效性的研究。使用RevMan 5.4软件对提取数据的风险比(RR)及其95%置信区间(95% CI)进行了汇总。我们在国际系统综述前瞻性注册中心(PROSPERO)注册了我们的方案(注册号:CRD42024529986):结果:我们纳入了九项研究,共计 65196 名患者,这些研究设计各不相同,涉及全球人群。分析显示,继续服用阿司匹林会显著增加结膜下出血的风险(RR:1.74,95% CI:1.22,2.50,P = .002)。然而,在继续服用阿司匹林组与停用阿司匹林组或阿司匹林组与安慰剂组之间,眼底出血、球后出血、玻璃体出血、眼压飙升、角膜水肿、后囊破裂和视力变化的风险没有显著差异:结论:虽然在白内障手术前使用阿司匹林会增加结膜下出血的可能性,但并不会增加可能危及视力的出血事件的风险。我们建议接受白内障手术的患者继续服用阿司匹林。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Accounts of Chemical Research
Accounts of Chemical Research 化学-化学综合
CiteScore
31.40
自引率
1.10%
发文量
312
审稿时长
2 months
期刊介绍: Accounts of Chemical Research presents short, concise and critical articles offering easy-to-read overviews of basic research and applications in all areas of chemistry and biochemistry. These short reviews focus on research from the author’s own laboratory and are designed to teach the reader about a research project. In addition, Accounts of Chemical Research publishes commentaries that give an informed opinion on a current research problem. Special Issues online are devoted to a single topic of unusual activity and significance. Accounts of Chemical Research replaces the traditional article abstract with an article "Conspectus." These entries synopsize the research affording the reader a closer look at the content and significance of an article. Through this provision of a more detailed description of the article contents, the Conspectus enhances the article's discoverability by search engines and the exposure for the research.
期刊最新文献
Management of Cholesteatoma: Hearing Rehabilitation. Congenital Cholesteatoma. Evaluation of Cholesteatoma. Management of Cholesteatoma: Extension Beyond Middle Ear/Mastoid. Recidivism and Recurrence.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1